Brain Tumors 101 Series: “MGMT Methylation in Glioblastoma Brain Tumors”

http://youtu.be/Ypp-VQEp42Y
BrainCancer.org presents its 6th video in the Brain Tumors 101 series, “MGMT Methylation in Glioblastoma Brain Tumors”. This is Part 2 of 2 on MGMT Methylation. Topics discussed in this video include: Temozolomide and impact on MGMT Methylated and Unmethylated glioblastoma brain tumors, prognosis for unmethylated vs methylated brain tumors, and details on how to understand what MGMT Methylation really means for the treatment of glioblastoma brain tumors.

One comment:

  1. Hi Dr. Cobbs,

    In this video you indicate that OS for MGMT methylation is 21.7 months vs 12.7 for unmethylated using the Stupp protocol.

    I have also seen that EGFR expressed patients have a OS of 34 month vs 12 for non-EGFR expressing patients if metronomic Temodar is utilized: http://www.healio.com/hematology-oncology/neuro-oncology/news/online/%7B22afa4c7-6ad2-45b7-bc98-4c98b6333341%7D/metronomic-temozolomide-extends-pfs-os-in-egfr–amplified-glioblastoma

    The EGFR study appears to be less credible (retroactive study) but it indicates a much longer OS.

    My question is, for people like me that have both methylated MGMT and express EGFR, how do you choose between Stupp(5/23) and metronomic Temodar regiments.

    Any input is appreciated.

    Thanks,
    Mike

Leave a Reply